Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Feb 2023
Price :
$35
*
At a glance
- Drugs Vandetanib (Primary)
- Indications Thyroid cancer
- Focus Registrational; Therapeutic Use
- Acronyms VERIFY
- Sponsors AstraZeneca; Sanofi Genzyme
- 06 Jan 2023 Status changed from active, no longer recruiting to completed.
- 19 Aug 2022 This trial has been completed in France, according to European Clinical Trials Database record. (10 Jan 2022)
- 20 Oct 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.